研究单位：[1]Chongqing Precision Biotech Co., Ltd[2]Beijing Children's Hospital[3]Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology[4]Beijing GoBroad Boren Hospital,Beijing,Beijing,China,100000[5]Pediatric Hematology department of Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[6]Xiehe Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[7]The Second Xiangya Hospital, Central South University,Changsha,Hunan,China,410000[8]Children's Hospital Of Soochow University,Suzhou,Jiangsu,China,215000[9]The First Affiliated Hospital Of Nanchang University,Nanchang,Jiangxi,China,330000[10]West China Second University Hospital,Sichuan University,Chengdu,Sichuan,China,610000[11]Institute Of Hematology&Blood Diseases Hospital,Chinese Academy Of Medicai Sciences,Tianjin,Tianjin,China,300000
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
